Headlands Technologies LLC Acquires 5,530 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Headlands Technologies LLC increased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 931.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 6,124 shares of the biopharmaceutical company’s stock after purchasing an additional 5,530 shares during the period. Headlands Technologies LLC’s holdings in Ultragenyx Pharmaceutical were worth $252,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of RARE. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $33,000. UMB Bank n.a. lifted its position in Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 352 shares during the period. GAMMA Investing LLC boosted its holdings in Ultragenyx Pharmaceutical by 622.3% in the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 865 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Ultragenyx Pharmaceutical by 67.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 1,339 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 140.9% during the 1st quarter. Lazard Asset Management LLC now owns 4,160 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,433 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $58.74 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $31.52 and a one year high of $59.76. The company’s fifty day moving average price is $50.12 and its 200-day moving average price is $46.24. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -7.30 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to analysts’ expectations of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The business’s quarterly revenue was up 35.7% on a year-over-year basis. During the same period last year, the firm earned ($2.25) earnings per share. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on RARE shares. Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Cantor Fitzgerald upped their price target on shares of Ultragenyx Pharmaceutical from $115.00 to $116.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Wedbush raised their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, Stifel Nicolaus lifted their price target on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.43.

Insider Buying and Selling

In related news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares in the company, valued at $124,209,562.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 40,675 shares of company stock valued at $2,149,446. Corporate insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.